Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study

View ORCID ProfileJu Hwan Kim, View ORCID ProfileYeon-Hee Baek, Hyesung Lee, View ORCID ProfileYoung June Choe, Hyun Joon Shin, Ju-Young Shin
doi: https://doi.org/10.1101/2020.07.29.20164822
Ju Hwan Kim
aSchool of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ju Hwan Kim
Yeon-Hee Baek
aSchool of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yeon-Hee Baek
Hyesung Lee
aSchool of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young June Choe
bDivision of Infectious Diseases, Department of Social and Preventive Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Young June Choe
Hyun Joon Shin
cDepartment of Medicine, Brigham and Women’s Hospital, Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ju-Young Shin
aSchool of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
dSamsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shin.jy@skku.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

There is ongoing debate as to whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) use is associated with poor prognosis of coronavirus disease-2019 (COVID-19). We sought to investigate the association between ACEI/ARB use and risk of poor clinical outcomes from COVID-19. We identified 1,290 patients with hypertension, of which 682 had recorded ACEI/ARB use and 608 without the use during 30 days preceding the date of COVID-19 diagnosis in completely enumerated COVID-19 cohort in South Korea. Our primary endpoint was the clinical outcomes comprised of all-cause mortality, use of mechanical ventilation, intensive care unit (ICU) admission, and sepsis. We used inverse probability of treatment weighting (IPTW) to mitigate selection bias, and Poisson regression model to estimate the relative risks (RR) and 95% confidence intervals (CI) to compare outcomes in ACEI/ARB users with non-users. Compared to non-use, ACEI/ARB use was associated with lower clinical outcomes (IPTW adjusted RR, 0.60; 95% CI, 0.42-0.85; p=0.0046). When assessed by individual outcomes, ACEI/ARB use was not associated with all-cause mortality (IPTW adjusted RR, 0.62; 95% CI, 0.35-1.09; p=0.0973) and respiratory events (IPTW adjusted RR, 0.99; 95% CI, 0.84-1.17; p=0.9043). Subgroup analysis showed a trend toward protective role of ACEIs and ARBs against overall outcomes in men (IPTW adjusted RR, 0.84; 95% CI, 0.69-1.03; p-for-interaction=0.008) and with pre-existing respiratory disease (IPTW adjusted RR, 0.74; 95% CI, 0.60-0.92; p-for-interaction=0.0023). We present clinical evidence to support continuing ACE/ARB use in completely enumerated hypertensive COVID-19 cohort in South Korea.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the Government-wide R&D Fund project for infectious disease research through the Government-wide R&D Fund for Infectious Disease Research (GFID) funded by the Korea Health Industry Development Institute of Republic of Korea (No. HG18C0068).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Our study complies with the Declaration of Helsinki and the study protocol was approved by the Institutional Review Board (IRB) of Sungkyunkwan University (SKKU 2020-03-021) and obtaining informed consent was waived by the IRB

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This study was supported by the Government-wide R&D Fund project for infectious disease research through the Government-wide R&D Fund for Infectious Disease Research (GFID) funded by the Korea Health Industry Development Institute of Republic of Korea (No. HG18C0068).

  • Disclosures: Dr. JY Shin report receipt of research funding from the Ministry of Food and Drug Safety, Ministry of Health and Welfare, and National Research Foundation of Republic of Korea; grants from pharmaceutical companies including Amgen, Pfizer, Hoffmann-La Roche, Dong-A ST, Yungjin outside the submitted work.

  • No other disclosures were reported.

Data Availability

No additional data available

https://hira-covid19.net/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted August 01, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study
Ju Hwan Kim, Yeon-Hee Baek, Hyesung Lee, Young June Choe, Hyun Joon Shin, Ju-Young Shin
medRxiv 2020.07.29.20164822; doi: https://doi.org/10.1101/2020.07.29.20164822
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study
Ju Hwan Kim, Yeon-Hee Baek, Hyesung Lee, Young June Choe, Hyun Joon Shin, Ju-Young Shin
medRxiv 2020.07.29.20164822; doi: https://doi.org/10.1101/2020.07.29.20164822

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5219)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5823)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1994)
  • Radiology and Imaging (345)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)